Objective: Cytotoxic factor is a unique pathogenesis-associated cytokine that is produced in mice (mCF) and man (hCF) during dengue virus infection. This study was undertaken to investigate the prevalence of hCF and its relationship to the duration and severity of the illness, and to ascertain its role, if any, in the pathogenesis of dengue fever (DF) and dengue haemorrhagic fever (DHF). Methods: Peripheral venous blood was collected from the patients of various grades and on different days after the onset of clinical illness. Sera were collected from a total of 333 cases, and analysed for the presence of hCF by inhibition ELISA and dot blot tests. Result: The positivity for hCF was 100% in cases of DHF grades III and IV, while overall positivity was seen in 295 out of 333 (88%) cases studied. Sera collected from the 1st to the 20th day of illness were positive for hCF. This was not seen at later periods. A majority of cases (52%) were below 15 years of age and peak positivity of 96% was noticed in the age-group of 11–15 years. The mean inhibition value of the ELISA was lowest (40 ± 8%) in cases of DF and was highest (70 ± 10%) in DHF grade IV, and the peak titres were found on the first 4 days of the illness. Conclusion: The findings show the presence of hCF in the majority of cases. It is detectable up to the 20th day of illness and may suggest an association of higher levels of hCF with the onset and severity of the illness.

Keywords:
Dengue haemorrhagic fever, Dengue virus, Cytotoxic factor, Cytokine
This content is only available via PDF.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.